DeeperML

Isomorphic Labs, a Google DeepMind spinoff, has secured $600 million in its first external funding round to boost its AI-driven drug discovery efforts. The funding round was led by Thrive Capital, with participation from GV and Alphabet, Isomorphic Labs’ existing investor. This significant investment highlights the growing confidence in the potential of AI to revolutionize pharmaceutical research.

The funds will be used to advance Isomorphic's AI drug design engine and therapeutic programs, with a focus on oncology and immunology. The company aims to accelerate the development of new treatments by applying artificial intelligence to the drug development process. Their key technology, AlphaFold 3, developed with Google DeepMind, predicts molecular structures with unprecedented precision.

Isomorphic Labs already has collaborations with pharmaceutical giants such as Eli Lilly and Novartis. Founder and CEO of Isomorphic Labs, Sir Demis Hassabis, stated that the funding will "further turbocharge the development of our next-generation AI drug design engine, help us advance our own programs into clinical development, and is a significant step forward towards our mission of one day solving all disease with the help of AI.”

ImgSrc: www.gzeromedia.

References :

• Crunchbase News: Google spinoff Isomorphic Labs raised $600 million in its first external funding round as the company looks to apply artificial intelligence to the drug development process.
• Maginative: AI-first drug design company Isomorphic Labs has raised $600 million in its first external funding round, led by Thrive Capital, to advance its AI drug design engine and therapeutic programs.

Classification:

• HashTags: #GoogleDeepMind #TxGemma #AIDrugDiscovery
• Company: Google
• Target: Drug Discovery
• Product: TxGemma
• Feature: drug discovery
• Type: AI
• Severity: Informative